Who should not use Inspra?

Inspra is contraindicated in patients with known hypersensitivity to eplerenone, severe renal impairment (eGFR 5.0 mmol/L). Caution is also advised for individuals taking other potassium‑raising agents.

Inspra

Active Ingredient:: Eplerenone
Origin:: EU

Inspra (Eplerenone)

Q: What is Inspra used for?

Inspra contains eplerenone, an aldosterone antagonist indicated for the treatment of hypertension, for heart failure with reduced ejection fraction, and for management after a myocardial infarction to reduce the risk of cardiovascular death and heart‑failure progression.

Q: What is the usual dose of Inspra?

The dose of Inspra is individualized by the prescribing clinician based on the patient’s condition, renal function, and serum potassium levels. The prescriber determines the appropriate starting dose and any subsequent titration.

Q: Is Inspra safe during pregnancy or breastfeeding?

Safety data for eplerenone in pregnancy and lactation are limited. It should only be used when the potential benefit outweighs the potential risk to the fetus or infant, and the decision should be made by the treating physician.

Q: How do I order Inspra from GNH India?

To order Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Q: How does Inspra compare with the main alternative drug?

The primary alternative within the same class is spironolactone. Eplerenone is more selective for the mineralocorticoid receptor, which generally results in fewer endocrine side effects such as gynecomastia, but both drugs share similar efficacy in controlling blood pressure and heart‑failure outcomes.

Q: How should Inspra be stored and handled?

Inspra tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Q: How is Inspra given or administered?

Inspra is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Q: What are the most serious risks to watch for while taking Inspra?

The most serious risks include severe hyperkalemia, which can cause cardiac arrhythmias, and acute kidney injury. Patients should have regular monitoring of serum potassium and renal function, and any symptoms such as muscle weakness, palpitations or sudden decrease in urine output should prompt immediate medical review.

Eplerenone, the active ingredient in Inspra, is an aldosterone antagonist presented as an oral tablet for oral use. It is employed to manage high blood pressure and certain forms of heart failure, particularly in patients with reduced ejection fraction or after myocardial infarction.

GNH India supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution networks across Europe, Asia, Africa and the Americas, ensuring consistent quality and regulatory compliance for each shipment globally.

Manufacturer / TM Owner

Upjohn Eesv

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Eplerenone is used in cardiovascular conditions that involve aldosterone‑mediated fluid retention and remodeling.

Hypertension: helps lower blood pressure by reducing sodium and water retention.
Heart failure (reduced ejection fraction): improves survival and reduces hospitalizations by decreasing cardiac remodeling.
Post‑myocardial infarction: lowers risk of cardiovascular death and heart failure progression when added to standard therapy.

How It Works

Eplerenone selectively blocks the mineralocorticoid (aldosterone) receptor in the distal nephron and cardiovascular tissues. By antagonizing aldosterone binding, it diminishes sodium reabsorption and potassium excretion, leading to natriuresis and reduced extracellular fluid volume. The blockade also attenuates aldosterone‑driven myocardial fibrosis and vascular inflammation, contributing to its antihypertensive and cardioprotective effects. These actions collectively help control blood pressure and limit adverse cardiac remodeling in patients with heart failure or after myocardial infarction.

Side Effects

Eplerenone may be associated with several adverse reactions, ranging from frequent to rare.

Common Side Effects

Hyperkalemia: elevated blood potassium levels, often mild.
Dizziness: feeling light‑headed or unsteady.
Headache: mild to moderate head pain.
Gastrointestinal discomfort: nausea, abdominal pain or diarrhea.

Serious or Rare Side Effects

Severe hyperkalemia: potentially life‑threatening high potassium requiring medical intervention.
Acute kidney injury: sudden decline in renal function.
Allergic reactions: rash, itching, swelling, or anaphylaxis.
Gynecomastia: breast tissue enlargement, reported rarely.

Precautions & Warnings

When prescribing Eplerenone, clinicians should consider several precautionary measures to ensure patient safety.

Monitor serum potassium: check baseline and periodic levels to avoid hyperkalemia.
Assess renal function: evaluate creatinine and eGFR before and during therapy.
Avoid use in severe renal impairment: contraindicated when eGFR <30 mL/min.
Caution in patients on potassium‑sparing diuretics or ACE inhibitors: risk of additive potassium rise.
Pregnancy and breastfeeding: use only if potential benefit justifies potential risk, as safety data are limited.
Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Avoid Interactions

Eplerenone can interact with other medicines that affect potassium balance or renal function.

Major Interactions (Avoid)

ACE inhibitors, ARBs, or potassium‑sparing diuretics: may cause dangerous hyperkalemia.
NSAIDs (e.g., ibuprofen, naproxen): can impair renal clearance and raise potassium.
CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase eplerenone plasma levels.

Moderate Interactions (Monitor Closely)

Digoxin: altered serum levels may require dose adjustment.
Lithium: concurrent use may increase lithium toxicity.
Antihypertensive agents: additive blood pressure lowering may require monitoring.

Frequently Asked Questions

Inspra contains eplerenone, an aldosterone antagonist indicated for the treatment of hypertension, for heart failure with reduced ejection fraction, and for management after a myocardial infarction to reduce the risk of cardiovascular death and heart‑failure progression.

Eplerenone selectively blocks the mineralocorticoid (aldosterone) receptor in the kidney and cardiovascular tissues. This antagonism reduces sodium reabsorption and potassium loss, leading to lower fluid volume, and also diminishes aldosterone‑driven cardiac fibrosis and vascular inflammation.

The dose of Inspra is individualized by the prescribing clinician based on the patient’s condition, renal function, and serum potassium levels. The prescriber determines the appropriate starting dose and any subsequent titration.

Safety data for eplerenone in pregnancy and lactation are limited. It should only be used when the potential benefit outweighs the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

The primary alternative within the same class is spironolactone. Eplerenone is more selective for the mineralocorticoid receptor, which generally results in fewer endocrine side effects such as gynecomastia, but both drugs share similar efficacy in controlling blood pressure and heart‑failure outcomes.

Inspra tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Inspra is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

The most serious risks include severe hyperkalemia, which can cause cardiac arrhythmias, and acute kidney injury. Patients should have regular monitoring of serum potassium and renal function, and any symptoms such as muscle weakness, palpitations or sudden decrease in urine output should prompt immediate medical review.

Inspra is contraindicated in patients with known hypersensitivity to eplerenone, severe renal impairment (eGFR <30 mL/min), or baseline hyperkalemia (serum potassium >5.0 mmol/L). Caution is also advised for individuals taking other potassium‑raising agents.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 09 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.